Literature DB >> 25076296

Pathologic T1 subclassification of ampullary carcinoma with perisphincteric or duodenal submucosal invasion: Is it T1b?

DongDo You1, JinSeok Heo, SeongHo Choi, DongWook Choi, Kee-Taek Jang.   

Abstract

CONTEXT: In ampullary carcinoma staging, T1 is defined as a tumor limited to the ampulla of Vater or the sphincter of Oddi, and T2 is defined as invasion into the duodenal wall. However, the definition of duodenal wall invasion is vague. Ampullary carcinoma that invades beyond the sphincteric of Oddi (perisphincteric invasion) or into the duodenal submucosa could be considered pT1b because submucosal invasion is classified as pT1b in gastrointestinal tract tumors. However, there are no data regarding T subclassifications for ampullary carcinoma with perisphincteric or duodenal submucosa invasion.
OBJECTIVE: To determine the T subclassification of ampullary carcinoma that invades into perisphincteric or duodenal submucosa.
DESIGN: Pathologically proven ampullary carcinomas with T1 or T2 were reviewed (n = 105). We reclassified tumors as pT1a that were limited to within the sphincter of Oddi (n = 40; 38%), as pT1b for tumors that invaded beyond the sphincter of Oddi or into the duodenal submucosa (n = 25; 24%), and as pT2 for tumors that invaded into duodenal proper muscle (n = 40; 38%).
RESULTS: Lymph node metastasis and recurrence were absent in ampullary carcinoma with pT1a, whereas nodal metastasis were noted in 24% (6 of 25) and 40% (16 of 40) of the ampullary carcinomas with pT1b and pT2, respectively. Tumor recurrence/metastasis rate of ampullary carcinoma with pT1b and pT2 was 44% (11 of 25) and 40% (16 of 40), respectively. The 5-year disease-free-survival rates from ampullary carcinoma with pT1a, pT1b, and pT2 were 95% (38 of 40), 56% (14 of 25), and 58% (23 of 40), respectively (P = .003). The 5-year overall survival from ampullary carcinoma with pT1a, pT1b, and pT2 was 98% (39 of 40), 72% (18 of 25), and 60% (24 of 40), respectively.
CONCLUSIONS: The clinicopathologic outcome of ampullary carcinoma with a pT1b subclassification was worse than it was for T1a and approached the outcome for pT2.

Entities:  

Mesh:

Year:  2014        PMID: 25076296     DOI: 10.5858/arpa.2013-0324-OA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  7 in total

Review 1.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

2.  Can endoscopic papillectomy be curative for early ampullary adenocarcinoma of the ampulla of Vater?

Authors:  María-Victoria Alvarez-Sanchez; Inés Oria; Olivia B Luna; Jean Pialat; Rodica Gincul; Christine Lefort; Raphael Bourdariat; Fabien Fumex; Vincent Lepilliez; Jean Yves Scoazec; Angel Salgado-Barreira; Anne Isabelle Lemaistre; Bertrand Napoléon
Journal:  Surg Endosc       Date:  2016-08-16       Impact factor: 4.584

3.  Does ampullary adenoma size predict invasion on EUS? Does invasion on EUS predict presence of malignancy?

Authors:  Vaishali Patel; Paul Jowell; Jorge Obando; Cynthia D Guy; Rebecca A Burbridge
Journal:  Endosc Int Open       Date:  2016-12

4.  A nomogram for predicting the probability of recurrence in patients with carcinomas located in the ampulla of Vater.

Authors:  Keng-Hao Liu; Chih-Ho Hsu; Jun-Te Hsu; Chun-Yi Tsai; Yu-Yin Liu; Tsann-Long Hwang; Ta-Sen Yeh; Yu-Shin Hung; Wen-Chi Chou
Journal:  J Cancer       Date:  2017-02-10       Impact factor: 4.207

5.  Advantage of endoscopic papillectomy for ampullary tumors as an alternative treatment for pancreatoduodenectomy.

Authors:  Shohei Abe; Arata Sakai; Atsuhiro Masuda; Mika Miki; Yoshiyuki Harada; Kae Nagao; Noriko Inomata; Shinya Kohashi; Hisahiro Uemura; Shigeto Masuda; Shigeto Ashina; Masanori Gonda; Kohei Yamakawa; Masahiro Tsujimae; Yasutaka Yamada; Takeshi Tanaka; Takashi Kobayashi; Ryota Nakano; Hideyuki Shiomi; Daisuke Tsugawa; Hiroaki Yanagimoto; Tetsuo Ajiki; Maki Kanzawa; Takumi Fukumoto; Tomoo Itoh; Yuzo Kodama
Journal:  Sci Rep       Date:  2022-09-07       Impact factor: 4.996

6.  Neuroendocrine tumor of the ampulla of Vater with distant cystic lymph node metastasis: a case report.

Authors:  Mariko Tsukagoshi; Yasuo Hosouchi; Kenichiro Araki; Yasushi Mochida; Ryusuke Aihara; Ken Shirabe; Hiroyuki Kuwano
Journal:  Surg Case Rep       Date:  2016-07-25

Review 7.  Ampulla of Vater carcinoma: Molecular landscape and clinical implications.

Authors:  Antonio Pea; Giulio Riva; Riccardo Bernasconi; Elisabetta Sereni; Rita Teresa Lawlor; Aldo Scarpa; Claudio Luchini
Journal:  World J Gastrointest Oncol       Date:  2018-11-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.